Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 1Carcinoma, Merkel Cell 1

Interventions

pembrolizumab 18Nivolumab 13avelumab 10Ipilimumab 7Specimen Handling 6cemiplimab 5atezolizumab 5Magnetic Resonance Spectroscopy 5Biopsy 5Radiotherapy 3Cyclophosphamide 3prednylidene 2poly ICLC 2lutetium Lu 177 dotatate 2fludarabine phosphate 2fludarabine 2durvalumab 2deltacortene 2aldesleukin 2Radiosurgery 2Prednisone 2Interleukin-2 2Immunoglobulin G 2Docetaxel 2CTLA-4 Antigen 2Bevacizumab 2tocilizumab 1talimogene laherparepvec 1sargramostim 1relatlimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Merkel Cell × Lidocaine, Prilocaine Drug Combination × 1 year × Clear all
NCT06223659 2026-03-10

EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers

Ohio State University Comprehensive Cancer Center

Phase 2 Recruiting
100 enrolled
Dermatologic

Melanoma, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡